Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial.
Rivera F, Romero C, Jimenez-Fonseca P, Izquierdo-Manuel M, Salud A, Martínez E, Jorge M, Arrazubi V, Méndez JC, García-Alfonso P, Reboredo M, Barriuso J, Muñoz-Unceta N, Jimeno R, López C. Rivera F, et al. Among authors: izquierdo manuel m. Cancer Chemother Pharmacol. 2019 Jun;83(6):1175-1181. doi: 10.1007/s00280-019-03820-7. Epub 2019 Mar 29. Cancer Chemother Pharmacol. 2019. PMID: 30927036 Free PMC article. Clinical Trial.
Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial.
Rivera F, Izquierdo-Manuel M, García-Alfonso P, Martínez de Castro E, Gallego J, Limón ML, Alsina M, López L, Galán M, Falcó E, Manzano JL, González E, Muñoz-Unceta N, López C, Aranda E, Fernández E, Jorge M, Jiménez-Fonseca P. Rivera F, et al. Among authors: izquierdo manuel m. Eur J Cancer. 2021 Mar;145:158-167. doi: 10.1016/j.ejca.2020.12.005. Epub 2021 Jan 20. Eur J Cancer. 2021. PMID: 33485079 Clinical Trial.
Correction to: Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial.
Rivera F, Romero C, Jimenez-Fonseca P, Izquierdo-Manuel M, Salud A, Martínez E, Jorge M, Arrazubi V, Méndez JC, García-Alfonso P, Reboredo M, Barriuso J, Muñoz-Unceta N, Jimeno R, López C. Rivera F, et al. Among authors: izquierdo manuel m. Cancer Chemother Pharmacol. 2019 Dec;84(6):1365. doi: 10.1007/s00280-019-03964-6. Cancer Chemother Pharmacol. 2019. PMID: 31587095 Free PMC article.
Reduced folate carrier (RFC) as a predictive marker for response to pemetrexed in advanced non-small cell lung cancer (NSCLC).
Alvarez-Fernandez C, Perez-Arnillas Q, Ruiz-Echeverria L, Rodriguez-Rubi D, Sanchez-Lorenzo L, Li-Torres W, Izquierdo-Manuel M, Berros JP, Luque-Cabal M, Jimenez-Fonseca P, Villanueva-Palicio N, Esteban-Gonzalez E. Alvarez-Fernandez C, et al. Among authors: izquierdo manuel m. Invest New Drugs. 2014 Apr;32(2):377-81. doi: 10.1007/s10637-013-9992-1. Epub 2013 Aug 4. Invest New Drugs. 2014. PMID: 23912258